Nephros Acquires Substantially All Assets of GenArraytion, Inc.
July 12, 2021
Nephros, Inc. (Nasdaq: NEPH) acquired substantially all of the assets of GenArraytion, Inc., a Rockville, Maryland-based developer of infectious disease PCR assays and multiplexing technology. The acquisition gives Nephros access to GenArraytion's MultiFLEX bioassays and other proprietary assays, which will be integrated into Nephros' Pathogen Detection Systems platform, and GenArraytion's CEO Dr. R. Paul Schaudies will partner with Nephros' pathogen detection leadership.
- Buyers
- Nephros, Inc.
- Targets
- GenArraytion, Inc.
- Sellers
- GenArraytion, Inc.
- Industry
- Biotechnology
- Location
- Maryland, United States
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
AbCellera Acquires TetraGenetics
September 13, 2021
Biotechnology
AbCellera Biologics Inc. acquired TetraGenetics, Inc. in an all-cash transaction to integrate TetraGenetics' recombinant transmembrane protein expression platform into AbCellera's antibody discovery technology stack. The acquisition expands AbCellera's ability to generate antibodies against difficult-to-drug ion channels, GPCRs and other transmembrane targets, and includes upfront and milestone-based payments.
-
Charles River Laboratories Acquires Retrogenix
March 31, 2021
Biotechnology
Charles River Laboratories has acquired Retrogenix Limited, a UK-based contract research organization specializing in cell microarray technology for target receptor identification and off-target profiling. The transaction was for approximately £35 million in cash with up to an additional £5 million contingent on performance, and Retrogenix becomes part of Charles River's Discovery and Safety Assessment segment to expand large-molecule and cell therapy discovery capabilities.
-
Transnetyx Acquires Laragen
August 22, 2023
Biotechnology
Transnetyx, a Memphis-based provider of outsourced genetic services, has acquired Laragen, a sequencing and genetic services company in Culver City, California. The deal adds Sanger and next-generation sequencing (NGS) capabilities to Transnetyx's service portfolio to broaden its offerings for academic, government, and pharmaceutical research customers.
-
Eurobio Scientific Acquires GenDx (Genome Diagnostics B.V.)
October 4, 2022
Biotechnology
Paris-based Eurobio Scientific has acquired all outstanding shares of Dutch transplant diagnostics specialist GenDx (Genome Diagnostics B.V.), following a share purchase agreement signed on August 17. The acquisition expands Eurobio's molecular diagnostics portfolio in transplantation and secures the company legacy with proceeds funding a GenDx foundation established by the founders.
-
Twist Bioscience Acquires iGenomX
June 30, 2021
Biotechnology
Twist Bioscience acquired iGenomX, a developer of high-throughput multiplex NGS library preparation tools, to expand its NGS workflow capabilities and accelerate customer conversion from microarray genotyping to sequencing-based genotyping. The deal consideration was $35 million (combination of cash and Twist stock, plus up to $5 million contingent stock), and Twist expects modest near-term financial impact with incremental revenue from the acquired business in fiscal 2023.
-
NeoGenomics Acquires Pathline
April 7, 2025
Healthcare Services
NeoGenomics, Inc. (NASDAQ: NEO) has completed its acquisition of Pathline, LLC, a CLIA/CAP/NYS-certified pathology laboratory headquartered in Ramsey, New Jersey. The deal strengthens NeoGenomics' commercial presence in the Northeast United States and expands its molecular and hematology-oncology testing capabilities and access to its oncology test menu.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.